ADAM17

Across TCGA pan-cancer cohorts, ADAM17 RNA differs between tumor and matched normal tissue in 13 of 18 cancer types tested, making tumor–normal expression one of ADAM17’s most consistent transcriptional readouts.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where ADAM17 RNA is more highly expressed in tumor relative to normal tissue. In most cancer types ADAM17 is over-expressed in tumor, although a few such as KICH show the opposite, repressed pattern.

HNSC, BLCA, and COAD are the cancer types where ADAM17 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in ADAM17 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
HNSC	All	III,IV	+1.412	<.001	12	view →
BLCA	Male	III,IV	+1.935	<.001	11	view →
COAD	Male	II,III,IV	+0.602	<.001	11	view →
KIRC	All	All	+0.494	<.001	8	view →
STAD	All	II,III,IV	+0.941	<.001	7	view →
READ	All	III,IV	+0.845	<.001	6	view →
LIHC	All	All	+0.574	<.001	6	view →
CHOL	Male	All	+2.366	<.001	5	view →
KICH	Female	II,III,IV	−1.451	<.001	5	view →
KIRP	All	II,III,IV	+0.914	.008	5	view →
LUSC	Male	All	+0.595	<.001	4	view →
ESCA	All	All	+0.997	.005	2	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 12 strongest of 13 lineages.

ADAM17–HNSC

Open the HNSC breakdown →